

Rubraca® (rucaparib) - Voluntary indication withdrawal

- On June 10, 2022, the <u>FDA approved</u> a voluntary indication withdrawal for Clovis Oncology's <u>Rubraca (rucaparib)</u>, for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies.
- This decision does not affect the other approved indications for Rubraca, which include:
 - Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy; and
 - Treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)associated metastatic castration-resistant prostate cancer who have been treated with
 androgen receptor-directed therapy and a taxane-based chemotherapy. Patients should
 be selected for therapy based on an FDA-approved companion diagnostic for Rubraca.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.